Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population

• Published in: Acta dermato-venereologica Vol. 104
• Main Authors: SIGURDARDOTTIR, Gunnthorunn, ALSTERHOLM, Mikael, ANDERSON, Chris D., BRADLEY, Maria, SANDSTRÖM FALK, MariHelen, JOHANSSON, Emma K., LUNDQVIST, Maria, SONESSON, Andreas, SVENSSON, Åke, THEODOSIOU, Grigorios, VRANG, Sophie, von KOBYLETZKI, Laura B.
• Format: Journal Article
• Language: English
• Published: MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica 19.06.2024
• Subjects: atopic dermatitis; Clinical Medicine; Dermatologi och venereologi; Dermatology and Venereal Diseases; eczema; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Original Report; patient-reported outcome measure; validation study
• ISSN: 0001-5555; 1651-2057
• DOI: 10.2340/actadv.v104.38889

A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD TM ). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27–48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD TM scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-AD TM was observed ( p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluated by vIGA-AD TM , affected RECAP scores significantly ( p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows acceptable reliability. SIGNIFICANCE The Recap of atopic eczema questionnaire is a new long-term outcome measure to evaluate disease control in patients with atopic dermatitis. The Harmonizing Outcome Measures for Eczema initiative has recommended Recap of atopic eczema questionnaire as a core outcome measure to be used in all clinical trials. This validation enables the use of Recap of atopic eczema questionnaire to evaluate and compare long-term atopic dermatitis control in routine healthcare and clinical research in Sweden.